Osta Reports Listing Transfer to NEX

THE ISSUE OF THIS PRESS RELEASE IS LIMITED TO CANADA ONLY. THIS PRESS RELEASE
SHOULD NOT BE ISSUED IN THE UNITED STATES THROUGH U.S. NEWS WIRE AGENCIES.


Osta Biotechnologies Inc. (the "Corporation") (TSX VENTURE:OBI) announces that
the TSX Venture Exchange (the "Exchange") has transferred its listing to the NEX
board of the Exchange (the "NEX") effective as of the opening of trading on
Friday, August 3, 2012. The Corporation's share symbol will remain OBI and the
common shares will remain suspended. 


The Corporation continues to review and consider several business opportunities
and its transfer to the NEX will not materially impact this strategy. 


Osta Biotechnologies Inc.

Osta is a biopharmaceutical company listed on the TSX Venture Exchange (TSX
VENTURE:OBI) currently focusing on developing therapeutics for Cancer and
Alzheimer's disease.


Certain information in this press release is forward-looking and is subject to
numerous risks and uncertainties. By their nature, such forward-looking
statements involve risks and uncertainties that could cause actual results to
differ materially from those contemplated by the forward-looking statements.
These risks include actions of Osta's competitors, and those inherent in
scientific research and development.